Penelope Ward

7.3k total citations · 3 hit papers
43 papers, 5.3k citations indexed

About

Penelope Ward is a scholar working on Epidemiology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Penelope Ward has authored 43 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Epidemiology, 15 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Penelope Ward's work include Influenza Virus Research Studies (22 papers), Respiratory viral infections research (13 papers) and Receptor Mechanisms and Signaling (10 papers). Penelope Ward is often cited by papers focused on Influenza Virus Research Studies (22 papers), Respiratory viral infections research (13 papers) and Receptor Mechanisms and Signaling (10 papers). Penelope Ward collaborates with scholars based in United States, United Kingdom and Switzerland. Penelope Ward's co-authors include Roger Mills, Regina Dutkowski, Nelson Kinnersley, Frederick G. Hayden, Frederick G. Hayden, Joseph Massarella, John J. Treanor, Ian Small, Sudeep Singh and David Ipe and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Penelope Ward

42 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza

2000 781 citations John J. Treanor, Frederick G. Hayden et al. JAMA profile →
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial

2000 606 citations Nelson Kinnersley, Penelope Ward et al. profile →
Oral oseltamivir treatment of influenza in children

2001 541 citations Richard J. Whitley, Frederick G. Hayden et al. The Pediatric Infectious Disease Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Penelope Ward United States	24	4.2k	1.1k	884	385	380	43	5.3k
Frederick G. Hayden United States	40	4.2k 1.0×	1.7k 1.5×	493 0.6×	342 0.9×	258 0.7×	85	6.4k
Fred Y. Aoki Canada	24	2.6k 0.6×	989 0.9×	341 0.4×	279 0.7×	152 0.4×	74	3.9k
David S. Fedson United States	41	3.7k 0.9×	1.3k 1.1×	317 0.4×	215 0.6×	408 1.1×	109	5.0k
Grace Lui Hong Kong	42	3.5k 0.8×	2.6k 2.3×	1.1k 1.2×	201 0.5×	139 0.4×	171	6.1k
KH Chan Hong Kong	9	1.1k 0.3×	3.1k 2.8×	342 0.4×	190 0.5×	553 1.5×	12	4.2k
Alan Wu Hong Kong	35	1.6k 0.4×	5.2k 4.6×	657 0.7×	264 0.7×	546 1.4×	81	7.5k
Regina Dutkowski United States	21	1.6k 0.4×	449 0.4×	499 0.6×	182 0.5×	147 0.4×	38	2.2k
Craig R. Rayner United States	31	1.6k 0.4×	1.4k 1.3×	732 0.8×	272 0.7×	96 0.3×	82	4.7k
Susan M. Poutanen Canada	26	1.2k 0.3×	2.9k 2.6×	474 0.5×	250 0.6×	241 0.6×	71	4.3k
Amy Sims United States	36	746 0.2×	5.5k 4.9×	1.3k 1.4×	262 0.7×	223 0.6×	76	7.2k

Countries citing papers authored by Penelope Ward

Since Specialization

Citations

This map shows the geographic impact of Penelope Ward's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Penelope Ward with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Penelope Ward more than expected).

Fields of papers citing papers by Penelope Ward

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Penelope Ward. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Penelope Ward. The network helps show where Penelope Ward may publish in the future.

Co-authorship network of co-authors of Penelope Ward

This figure shows the co-authorship network connecting the top 25 collaborators of Penelope Ward. A scholar is included among the top collaborators of Penelope Ward based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Penelope Ward. Penelope Ward is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Miller, Matthew P., Lale Kostakoğlu, Daniel A. Pryma, et al.. (2017). Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using ¹⁸F-Fluciclovine PET/CT. Journal of Nuclear Medicine. 58(10). 1596–1602. 26 indexed citations

Teoh, Eugene, David Bottomley, Andrew Scarsbrook, et al.. (2017). Impact of 18 F-fluciclovine PET/CT on Clinical Management of Patients with Recurrent Prostate Cancer: Results from the Phase 3 FALCON Trial. International Journal of Radiation Oncology*Biology*Physics. 99(5). 1316–1317. 5 indexed citations

Robson, Richard A., Adrian L. Buttimore, Kelvin L. Lynn, Mike Brewster, & Penelope Ward. (2006). The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrology Dialysis Transplantation. 21(9). 2556–2562. 41 indexed citations

Delmas, Pierre D., Silvano Adami, J. A. Stakkestad, et al.. (2006). Intravenous ibandronate injections in postmenopausal women with osteoporosis: One‐year results from the dosing intravenous administration study. Arthritis & Rheumatism. 54(6). 1838–1846. 191 indexed citations

Ward, Penelope, et al.. (2005). Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic. Journal of Antimicrobial Chemotherapy. 55(suppl_1). i5–i21. 349 indexed citations

Dutkowski, Regina, et al.. (2003). Safety and Pharmacology of Oseltamivir in Clinical Use. Drug Safety. 26(11). 787–801. 91 indexed citations

Kaiser, Laurent, Cynthia Wat, Tracy Mills, et al.. (2003). Impact of Oseltamivir Treatment on Influenza-Related Lower Respiratory Tract Complications and Hospitalizations. Archives of Internal Medicine. 163(14). 1667–1667. 356 indexed citations

Singh, Sudeep, et al.. (2003). Clinical Benefits with Oseltamivir in???Treating Influenza in Adult Populations. Clinical Drug Investigation. 23(9). 561–569. 36 indexed citations

Hill, George, Tomáš Cihlář, Charles Oo, et al.. (2002). The Anti-Influenza Drug Oseltamivir Exhibits Low Potential to Induce Pharmacokinetic Drug Interactions via Renal Secretion—Correlation of in Vivo and in Vitro Studies. Drug Metabolism and Disposition. 30(1). 13–19. 99 indexed citations

10.

Oo, Charles, Joanne Barrett, Albert Dorr, Baolian Liu, & Penelope Ward. (2002). Lack of Pharmacokinetic Interaction between the Oral Anti-Influenza Prodrug Oseltamivir and Aspirin. Antimicrobial Agents and Chemotherapy. 46(6). 1993–1995. 20 indexed citations

11.

Whitley, Richard J., Frederick G. Hayden, Keith S. Reisinger, et al.. (2001). Oral oseltamivir treatment of influenza in children. The Pediatric Infectious Disease Journal. 20(2). 127–133. 541 indexed citations breakdown →

12.

Gravenstein, Stefan, et al.. (2001). Long‐Term Use of Oseltamivir for the Prophylaxis of Influenza in a Vaccinated Frail Older Population. Journal of the American Geriatrics Society. 49(8). 1025–1031. 139 indexed citations

13.

Oo, Charles, Joanne Barrett, George Hill, et al.. (2001). Pharmacokinetics and Dosage Recommendations for an Oseltamivir Oral Suspension for the Treatment of Influenza in Children. Pediatric Drugs. 3(3). 229–236. 67 indexed citations

14.

Dorr, Albert, et al.. (2000). The Comparative Pharmacokinetics and Safety of the Oral Neuraminidase Inhibitor Oseltamivir when Given in Multiple Doses to Healthy Japanese and Caucasian Subjects.. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 31(2). 397–398. 1 indexed citations

15.

Treanor, John J., Frederick G. Hayden, Rick A. Barbarash, et al.. (2000). Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza. JAMA. 283(8). 1016–1016. 781 indexed citations breakdown →

16.

Massarella, Joseph, et al.. (2000). The Pharmacokinetics and Tolerability of the Oral Neuraminidase Inhibitor Oseltamivir (Ro 64–0796/GS4104) in Healthy Adult and Elderly Volunteers. The Journal of Clinical Pharmacology. 40(8). 836–843. 73 indexed citations

17.

Massarella, Joseph, et al.. (1999). Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802. Clinical Pharmacokinetics. 37(6). 471–484. 326 indexed citations

18.

Hayden, Frederick G., Robert L. Atmar, M. Schilling, et al.. (1999). Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza. New England Journal of Medicine. 341(18). 1336–1343. 384 indexed citations

19.

Hayden, Frederick G., John J. Treanor, Richard Fritz, et al.. (1999). Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza. JAMA. 282(13). 1240–1240. 443 indexed citations

20.

Fleishaker, Joseph C., et al.. (1994). Effect of age and gender on tirilazad pharmacokinetics in humans. Clinical Pharmacology & Therapeutics. 55(4). 378–384. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact